Abstract

BackgroundPrognostic and predictive significance of epidermal growth factor receptor (EGFR) in colorectal carcinomas (CRCs) is still controversial. The aim of the present study was to explore and correlate membrane and nuclear EGFR and cyclin-D1 protein expression with EGFR gene status of tumor cells.MethodsImmunohistochemical and FISH analysis was performed on 135 archival formalin fixed and paraffin embedded CRCs.ResultsStrong membrane and strong nuclear EGFR staining was detected in 16% and 57% of cases, respectively, and strong cyclin-D1 expression in 57% samples. Gene EGFR amplification was identified in 5.9% and polysomy in 7.4% of cases, while 87% showed no EGFR gene changes. A statistically significant difference was only found between tumor grade and expression of membrane EGFR, while nuclear EGFR and cyclin-D1 expression was not associated with the clinicopathologic characteristics analyzed. Tumor cells displaying gene amplification and strong protein membrane EGFR expression overlapped, while EGFR gene status showed no correlation with nuclear EGFR and cyclin-D1. There was no association between membrane EGFR and cyclin-D1, whereas nuclear EGFR expression was strongly related to cyclin-D1 expression.ConclusionsStudy results revealed heterogeneity among CRCs, which could have a predictive value by identifying biologically and probably clinically different subsets of tumors with the possibly diverse response to anti-EGFR therapies.

Highlights

  • Prognostic and predictive significance of epidermal growth factor receptor (EGFR) in colorectal carcinomas (CRCs) is still controversial

  • There was no association between membrane EGFR and cyclin-D1, whereas nuclear EGFR expression was strongly related to cyclin-D1 expression

  • Among 135 Colorectal cancer (CRC) analyzed for EGFR, we detected strong membrane staining in 22 (16.3%) and strong nuclear staining in 77 (57%) cases

Read more

Summary

Introduction

Prognostic and predictive significance of epidermal growth factor receptor (EGFR) in colorectal carcinomas (CRCs) is still controversial. The irinotecan and oxaliplatin have improved survival while the development of monoclonal antibodies against growth factor receptors, such as Department of Pathology, School of Medicine, University of Rijeka, 51000 Rijeka, Croatia. Full list of author information is available at the end of the article monoclonal antibodies against epidermal growth factor receptor (EGFR), has augmented their effects [2,3]. The receptor is a member of the ErbB family of receptor tyrosine kinases, including ErbB1, ErbB2 (HER-2), ErbB3, and. Overexpression of membrane EGFR (mEGFR) has been found to correlate with poor prognosis in several cancers, including colorectal [6,7].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call